Top 5 Companies in the Alzheimer’s Drugs Market in 2025

The Alzheimer’s drugs market was valued at USD 5.75 Billion in 2024. The market is expected to grow at a CAGR of 7.12% during the forecast period of 2025-2034, with the values likely to reach USD 11.44 Billion by 2034. The market is driven by the increasing aging population and rising awareness about Alzheimer's disease across the 8 major markets.

Alzheimer's drugs are aimed at alleviating and preventing the progression of a neurodegenerative condition like Alzheimer's, which causes issues in memory, cognition, and behavior. Drugs that are available in the market enhance cognitive functions, handle behavioral disorders, or address basic biological processes by attacking amyloid plaques and tau tangles, among others. A cure for the disease does not exist yet but the progress in drug development brings hope for treatments that may improve patient outcomes. Alzheimer's is the leading cause of dementia, mainly affecting older individuals. It is a challenge to healthcare systems due to its gradual debilitating course that affects the quality of life.

The rapid growth of the global market for Alzheimer's drugs is driven by the increased incidence of Alzheimer's disease and the aging population. With millions affected around the world, the surging demand for Alzheimer's disease treatments is boosting market size. The market consists of pharmacological as well as non-pharmacological approaches to arrest disease progression, alleviate symptoms, and improve patients' quality of life. Pharmaceutical companies are significantly investing in new categories of drugs such as monoclonal antibodies, enzyme inhibitors, and targeted therapies. New product approvals remain a driving force in the market.

In October 2024, the U.S. FDA approved Kisunla (donanemab-azbt), a groundbreaking treatment for Alzheimer's disease, offering a significant advancement in addressing this debilitating condition. The clinical trials demonstrated Kisunla's effectiveness in reducing cognitive decline among those with mild cognitive impairment or mild dementia. Kisunla, administered by intravenous infusion once a week, offers a promising new option for the people living with Alzheimer's. This approval brings renewed hope for better patient outcomes while fueling the growing demand for innovative Alzheimer's therapies in the global healthcare market.

Let’s explore the profile of top companies leading the Alzheimer’s drugs market in 2025.

1.    F. Hoffmann-La Roche Ltd

Roche is the leader in the Alzheimer's medication market. The company is renowned for its groundbreaking research and innovative therapies for this illness. Roche has performed extensive studies on crenezumab, a trial antibody aimed at delaying the advancement of early-onset Alzheimer's. Roche remains one of the strongest committed parties in Alzheimer's research. In addition, the corporation is moving ahead with further promising candidates like gantenerumab, all of which are in trials. The strategic tie-ups with premier research groups add to Roche's research pipeline to identify and find effective treatment and even prevention methods for Alzheimer's disease.

2.    Biogen Inc.

Biogen Inc. is one of the leading global biotechnology companies, with leadership in developing first-in-class therapies in diseases, specifically, Alzheimer's disease. It collaborated with Eisai Co. Ltd for the development of the first-in-class anti-amyloid antibody LEQEMBI against early Alzheimer's disease, now established, based on the present state of evidence, to slow down the progression of the disease. The therapy was approved in several markets, including the United States, Japan, and China. Biogen, with a thorough understanding of neuroscience and constant research on Alzheimer's disease treatments, is committed to improving the lives of patients who suffer from neurodegenerative diseases.

3.    AbbVie Inc.

AbbVie, the world's leader in global biopharmaceutical development, continues to push advancement in Alzheimer's treatment via its acquisition of Aliada Therapeutics in October 2024. Aliada's technology enables drugs to cross the blood-brain barrier (BBB), accelerating the development of Alzheimer’s therapies, including its lead candidate, ALIA-1758, an anti-amyloid beta antibody. Their neuroscience pipeline will propel forward and bring potentially transformative therapies to Alzheimer's and other central nervous system disorders. This strategic initiative by AbbVie is a commitment to the fulfillment of significant unmet medical needs in the treatment of neurological diseases.

4.    Eisai Co. Ltd

Eisai Co., Ltd., the leader in the global market for Alzheimer's treatments, received FDA approval for its innovative treatment, LEQEMBI ® (lecanemab-irmb), in July 2023. It has emerged as the first medication approved by the FDA that had proven to slow the worsening of disease and cognitive decline in people with early Alzheimer's disease. Co-developed with Biogen, LEQEMBI specifically targets amyloid plaques in Alzheimer's disease. This breakthrough is expected to enhance patient access, supported by expanded Medicare coverage and patient assistance programs.

5.    Ono Pharmaceutical Co. Ltd.

Ono Pharmaceutical Co., Ltd. is a notable global biopharmaceutical company dedicated to innovative drug development. The company has a robust strategy for expanding into neurodegenerative diseases, such as Alzheimer's. In January 2022, Ono enhanced its discovery of drugs through an expanded collaboration with Neurimmune AG. The partnership uses Neurimmune's Reverse Translational Medicine™ (RTM™) technology to develop human-derived monoclonal antibodies for new therapeutic targets for Alzheimer's and other neurodegenerative diseases. The collaboration supports Ono's efforts in the pursuit of developing treatments for these difficult conditions.